Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 775

1.

Altered body composition, sarcopenia, frailty, and their clinico-biological correlates, in Parkinson's disease.

Tan AH, Hew YC, Lim SY, Ramli NM, Kamaruzzaman SB, Tan MP, Grossmann M, Ang BH, Tan JY, Manap MAAA, Tay TK, Tan SL, New RP, Fadzli F, Yee EJ, Moy FM, Mahadeva S, Lang AE.

Parkinsonism Relat Disord. 2018 Jun 13. pii: S1353-8020(18)30279-7. doi: 10.1016/j.parkreldis.2018.06.020. [Epub ahead of print]

PMID:
29914840
2.

Repurposing drugs to treat l-DOPA-induced dyskinesia in Parkinson's disease.

Johnston TH, Lacoste AMB, Visanji NP, Lang AE, Fox SH, Brotchie JM.

Neuropharmacology. 2018 Jun 1. pii: S0028-3908(18)30270-3. doi: 10.1016/j.neuropharm.2018.05.035. [Epub ahead of print] Review.

PMID:
29907424
3.

Movement disorders in non-encephalopathic Hashimoto's thyroiditis.

Miranda M, Bustamante ML, Campero M, Wainstein E, Toche P, Espay AJ, Walker RH, Lang AE.

Parkinsonism Relat Disord. 2018 Jun 5. pii: S1353-8020(18)30267-0. doi: 10.1016/j.parkreldis.2018.06.008. [Epub ahead of print] No abstract available.

PMID:
29887356
4.

Current Concepts in Diagnosis and Treatment of Functional Neurological Disorders.

Espay AJ, Aybek S, Carson A, Edwards MJ, Goldstein LH, Hallett M, LaFaver K, LaFrance WC Jr, Lang AE, Nicholson T, Nielsen G, Reuber M, Voon V, Stone J, Morgante F.

JAMA Neurol. 2018 Jun 4. doi: 10.1001/jamaneurol.2018.1264. [Epub ahead of print]

PMID:
29868890
5.

Neuropsychiatric expression and catatonia in 22q11.2 deletion syndrome: An overview and case series.

Butcher NJ, Boot E, Lang AE, Andrade D, Vorstman J, McDonald-McGinn D, Bassett AS.

Am J Med Genet A. 2018 May 19. doi: 10.1002/ajmg.a.38708. [Epub ahead of print]

PMID:
29777584
6.

Regulation of myeloid cell phagocytosis by LRRK2 via WAVE2 complex stabilization is altered in Parkinson's disease.

Kim KS, Marcogliese PC, Yang J, Callaghan SM, Resende V, Abdel-Messih E, Marras C, Visanji NP, Huang J, Schlossmacher MG, Trinkle-Mulcahy L, Slack RS, Lang AE; Canadian Lrrk2 in Inflammation Team (CLINT), Park DS.

Proc Natl Acad Sci U S A. 2018 May 29;115(22):E5164-E5173. doi: 10.1073/pnas.1718946115. Epub 2018 May 14.

PMID:
29760073
7.

Diagnostic criteria for camptocormia in Parkinson's disease: A consensus-based proposal.

Fasano A, Geroin C, Berardelli A, Bloem BR, Espay AJ, Hallett M, Lang AE, Tinazzi M.

Parkinsonism Relat Disord. 2018 May 8. pii: S1353-8020(18)30224-4. doi: 10.1016/j.parkreldis.2018.04.033. [Epub ahead of print]

PMID:
29759930
8.

Sleep-related motor and behavioral disorders: Recent advances and new entities.

Breen DP, Högl B, Fasano A, Trenkwalder C, Lang AE.

Mov Disord. 2018 May 14. doi: 10.1002/mds.27375. [Epub ahead of print] Review.

PMID:
29756278
9.

Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11.2.

Boot E, Butcher NJ, Udow S, Marras C, Mok KY, Kaneko S, Barrett MJ, Prontera P, Berman BD, Masellis M, Dufournet B, Nguyen K, Charles P, Mutez E, Danaila T, Jacquette A, Colin O, Drapier S, Borg M, Fiksinski AM, Vergaelen E, Swillen A, Vogels A, Plate A, Perandones C, Gasser T, Clerinx K, Bourdain F, Mills K, Williams NM, Wood NW, Booij J, Lang AE, Bassett AS; International Research Group on 22q11.2DS-associated Parkinson's Disease.

Neurology. 2018 Jun 5;90(23):e2059-e2067. doi: 10.1212/WNL.0000000000005660. Epub 2018 May 11.

10.

Emotion Detection Deficits and Decreased Empathy in Patients with Alzheimer's Disease and Parkinson's Disease Affect Caregiver Mood and Burden.

Martinez M, Multani N, Anor CJ, Misquitta K, Tang-Wai DF, Keren R, Fox S, Lang AE, Marras C, Tartaglia MC.

Front Aging Neurosci. 2018 Apr 24;10:120. doi: 10.3389/fnagi.2018.00120. eCollection 2018.

11.

Clustering of motor and nonmotor traits in leucine-rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study.

Mestre TA, Pont-Sunyer C, Kausar F, Visanji NP, Ghate T, Connolly BS, Gasca-Salas C, Kern DS, Jain J, Slow EJ, Faust-Socher A, Kasten M, Wadia PM, Zadikoff C, Kumar P, de Bie RM, Thomsen T, Lang AE, Schüle B, Klein C, Tolosa E, Marras C.

Mov Disord. 2018 Apr 17. doi: 10.1002/mds.27272. [Epub ahead of print]

PMID:
29665080
12.

Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations.

Lang AE, Espay AJ.

Mov Disord. 2018 May;33(5):660-677. doi: 10.1002/mds.27360. Epub 2018 Apr 11. Review.

PMID:
29644751
13.

Oculogyric crises in PLA2G6 associated neurodegeneration.

Rohani M, Shahidi G, Vali F, Lang AE, Slow E, Gahl WA, Behnam B.

Parkinsonism Relat Disord. 2018 Mar 17. pii: S1353-8020(18)30125-1. doi: 10.1016/j.parkreldis.2018.03.010. [Epub ahead of print] No abstract available.

PMID:
29574084
14.

A 21-Year Retrospective Study of the Toronto Western Hospital Deep Brain Stimulation Cohort.

Cubo E, Rajalingam R, Fasano A, Munhoz RP, Lang AE, Calvo S, Marras C.

Mov Disord. 2018 May;33(5):850-852. doi: 10.1002/mds.27359. Epub 2018 Mar 23. No abstract available.

PMID:
29570864
15.

Functional neurological disorders in Parkinson disease.

Wissel BD, Dwivedi AK, Merola A, Chin D, Jacob C, Duker AP, Vaughan JE, Lovera L, LaFaver K, Levy A, Lang AE, Morgante F, Nirenberg MJ, Stephen C, Sharma N, Romagnolo A, Lopiano L, Balint B, Yu XX, Bhatia KP, Espay AJ.

J Neurol Neurosurg Psychiatry. 2018 Jun;89(6):566-571. doi: 10.1136/jnnp-2017-317378. Epub 2018 Mar 16.

PMID:
29549192
16.

Actigraphy Detects Greater Intra-Individual Variability During Gait in Non-Manifesting LRRK2 Mutation Carriers.

van den Heuvel L, Lim AS, Visanji NP, Huang J, Ghate T, Mestre TA, AlDakheel A, Connolly BS, Gasca-Salas C, Kern DS, Jain J, Slow EJ, Pondal M, Faust-Socher A, Rogaeva E, Tomlinson G, Lang AE, Marras C.

J Parkinsons Dis. 2018;8(1):131-139. doi: 10.3233/JPD-171151.

PMID:
29480219
17.

Ataxia-telangiectasia: A review of movement disorders, clinical features, and genotype correlations.

Levy A, Lang AE.

Mov Disord. 2018 Feb 13. doi: 10.1002/mds.27319. [Epub ahead of print] Review.

PMID:
29436738
18.

[18F]-THK5351 PET Correlates with Topology and Symptom Severity in Progressive Supranuclear Palsy.

Brendel M, Schönecker S, Höglinger G, Lindner S, Havla J, Blautzik J, Sauerbeck J, Rohrer G, Zach C, Vettermann F, Lang AE, Golbe L, Nübling G, Bartenstein P, Furukawa K, Ishiki A, Bötzel K, Danek A, Okamura N, Levin J, Rominger A.

Front Aging Neurosci. 2018 Jan 17;9:440. doi: 10.3389/fnagi.2017.00440. eCollection 2017.

19.

Pallidal deep brain stimulation modulates cortical excitability and plasticity.

Ni Z, Kim SJ, Phielipp N, Ghosh S, Udupa K, Gunraj CA, Saha U, Hodaie M, Kalia SK, Lozano AM, Lee DJ, Moro E, Fasano A, Hallett M, Lang AE, Chen R.

Ann Neurol. 2018 Feb;83(2):352-362. doi: 10.1002/ana.25156.

PMID:
29369401
20.

Infantile-onset hand dystonia with intellectual disability: Clues to ARX mutations.

Breen DP, Mercimek-Andrews S, Lang AE.

Neurology. 2018 Feb 13;90(7):333-335. doi: 10.1212/WNL.0000000000004972. Epub 2018 Jan 17. No abstract available.

PMID:
29343471
21.

Exacerbation of psychosis triggered by a synthetic cannabinoid in a 70-year-old woman with Parkinson disease.

Udow SJ, Freitas ME, Fox SH, Lang AE.

CMAJ. 2018 Jan 15;190(2):E50-E52. doi: 10.1503/cmaj.170361. No abstract available.

PMID:
29335263
22.

What is "essential" about essential tremor? A diagnostic placeholder.

Fasano A, Lang AE, Espay AJ.

Mov Disord. 2018 Jan;33(1):58-61. doi: 10.1002/mds.27288. Epub 2017 Dec 22. No abstract available.

PMID:
29272067
23.

The combined fatigue effects of sequential exposure to seated whole body vibration and physical, mental, or concurrent work demands.

Yung M, Lang AE, Stobart J, Kociolek AM, Milosavljevic S, Trask C.

PLoS One. 2017 Dec 13;12(12):e0188468. doi: 10.1371/journal.pone.0188468. eCollection 2017.

24.

Asymmetric neuromodulation of motor circuits in Parkinson's disease: The role of subthalamic deep brain stimulation.

Lizarraga KJ, Luca CC, De Salles A, Gorgulho A, Lang AE, Fasano A.

Surg Neurol Int. 2017 Oct 24;8:261. doi: 10.4103/sni.sni_292_17. eCollection 2017. Review.

25.

Is there even such a thing as "idiopathic normal pressure hydrocephalus"?

Espay AJ, Lang AE.

Ann Neurol. 2017 Dec;82(6):1032. doi: 10.1002/ana.25097. Epub 2017 Dec 4. No abstract available.

PMID:
29136297
26.

Lymphatic vasculature in human dural superior sagittal sinus: Implications for neurodegenerative proteinopathies.

Visanji NP, Lang AE, Munoz DG.

Neurosci Lett. 2018 Feb 5;665:18-21. doi: 10.1016/j.neulet.2017.11.001. Epub 2017 Nov 11.

PMID:
29133178
27.

Impaired emotion processing in functional (psychogenic) tremor: A functional magnetic resonance imaging study.

Espay AJ, Maloney T, Vannest J, Norris MM, Eliassen JC, Neefus E, Allendorfer JB, Lang AE, Szaflarski JP.

Neuroimage Clin. 2017 Oct 18;17:179-187. doi: 10.1016/j.nicl.2017.10.020. eCollection 2018.

28.

Altered gut microbiome and metabolome in patients with multiple system atrophy.

Tan AH, Chong CW, Song SL, Teh CSJ, Yap IKS, Loke MF, Tan YQ, Yong HS, Mahadeva S, Lang AE, Lim SY.

Mov Disord. 2018 Jan;33(1):174-176. doi: 10.1002/mds.27203. Epub 2017 Oct 30. No abstract available.

PMID:
29083071
29.
30.

Levodopa and Parkinson Disease-Myths Revisited-Reply.

Espay AJ, Lang AE.

JAMA Neurol. 2017 Oct 1;74(10):1270-1271. doi: 10.1001/jamaneurol.2017.2563. No abstract available.

PMID:
28973085
31.

Caffeine as symptomatic treatment for Parkinson disease (Café-PD): A randomized trial.

Postuma RB, Anang J, Pelletier A, Joseph L, Moscovich M, Grimes D, Furtado S, Munhoz RP, Appel-Cresswell S, Moro A, Borys A, Hobson D, Lang AE.

Neurology. 2017 Oct 24;89(17):1795-1803. doi: 10.1212/WNL.0000000000004568. Epub 2017 Sep 27.

PMID:
28954882
32.

Deconstructing normal pressure hydrocephalus: Ventriculomegaly as early sign of neurodegeneration.

Espay AJ, Da Prat GA, Dwivedi AK, Rodriguez-Porcel F, Vaughan JE, Rosso M, Devoto JL, Duker AP, Masellis M, Smith CD, Mandybur GT, Merola A, Lang AE.

Ann Neurol. 2017 Oct;82(4):503-513. doi: 10.1002/ana.25046. Epub 2017 Oct 4. Review.

PMID:
28892572
33.

Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.

Obeso JA, Stamelou M, Goetz CG, Poewe W, Lang AE, Weintraub D, Burn D, Halliday GM, Bezard E, Przedborski S, Lehericy S, Brooks DJ, Rothwell JC, Hallett M, DeLong MR, Marras C, Tanner CM, Ross GW, Langston JW, Klein C, Bonifati V, Jankovic J, Lozano AM, Deuschl G, Bergman H, Tolosa E, Rodriguez-Violante M, Fahn S, Postuma RB, Berg D, Marek K, Standaert DG, Surmeier DJ, Olanow CW, Kordower JH, Calabresi P, Schapira AHV, Stoessl AJ.

Mov Disord. 2017 Sep;32(9):1264-1310. doi: 10.1002/mds.27115. Review.

PMID:
28887905
34.

[18F]AV-1451 binding to neuromelanin in the substantia nigra in PD and PSP.

Coakeley S, Cho SS, Koshimori Y, Rusjan P, Ghadery C, Kim J, Lang AE, Houle S, Strafella AP.

Brain Struct Funct. 2018 Mar;223(2):589-595. doi: 10.1007/s00429-017-1507-y. Epub 2017 Sep 7.

PMID:
28884232
35.

Recurrent Impulse Control Disorder Associated with Rasagiline Treatment of Parkinson's Disease.

Levy A, Lang AE.

Can J Neurol Sci. 2017 Jul;44(4):447-448. doi: 10.1017/cjn.2016.307. No abstract available.

PMID:
28767029
36.

Progressive ataxia and palatal tremor: Two autopsy cases of a novel tauopathy.

Gao AF, Faust-Socher A, Al-Murshed M, Del Bigio MR, Lang AE, Munoz DG.

Mov Disord. 2017 Oct;32(10):1465-1473. doi: 10.1002/mds.27074. Epub 2017 Jul 24.

PMID:
28736850
37.

Motor Phenotype in Neurodegenerative Disorders: Gait and Balance Platform Study Design Protocol for the Ontario Neurodegenerative Research Initiative (ONDRI).

Montero-Odasso M, Pieruccini-Faria F, Bartha R, Black SE, Finger E, Freedman M, Greenberg B, Grimes DA, Hegele RA, Hudson C, Kleinstiver PW, Lang AE, Masellis M, McLaughlin PM, Munoz DP, Strother S, Swartz RH, Symons S, Tartaglia MC, Zinman L, Strong MJ; ONDRI Investigators, McIlroy W.

J Alzheimers Dis. 2017;59(2):707-721. doi: 10.3233/JAD-170149.

38.

Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches.

Boxer AL, Yu JT, Golbe LI, Litvan I, Lang AE, Höglinger GU.

Lancet Neurol. 2017 Jul;16(7):552-563. doi: 10.1016/S1474-4422(17)30157-6. Epub 2017 Jun 13. Review.

39.

Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohorts.

Liu G, Locascio JJ, Corvol JC, Boot B, Liao Z, Page K, Franco D, Burke K, Jansen IE, Trisini-Lipsanopoulos A, Winder-Rhodes S, Tanner CM, Lang AE, Eberly S, Elbaz A, Brice A, Mangone G, Ravina B, Shoulson I, Cormier-Dequaire F, Heutink P, van Hilten JJ, Barker RA, Williams-Gray CH, Marinus J, Scherzer CR; HBS; CamPaIGN; PICNICS; PROPARK; PSG; DIGPD; PDBP.

Lancet Neurol. 2017 Aug;16(8):620-629. doi: 10.1016/S1474-4422(17)30122-9. Epub 2017 Jun 16.

PMID:
28629879
40.

A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY-PD III).

Biglan KM, Oakes D, Lang AE, Hauser RA, Hodgeman K, Greco B, Lowell J, Rockhill R, Shoulson I, Venuto C, Young D, Simuni T; Parkinson Study Group STEADY‐PD III Investigators.

Ann Clin Transl Neurol. 2017 May 9;4(6):360-368. doi: 10.1002/acn3.412. eCollection 2017 Jun.

41.

Which ante mortem clinical features predict progressive supranuclear palsy pathology?

Respondek G, Kurz C, Arzberger T, Compta Y, Englund E, Ferguson LW, Gelpi E, Giese A, Irwin DJ, Meissner WG, Nilsson C, Pantelyat A, Rajput A, van Swieten JC, Troakes C, Josephs KA, Lang AE, Mollenhauer B, Müller U, Whitwell JL, Antonini A, Bhatia KP, Bordelon Y, Corvol JC, Colosimo C, Dodel R, Grossman M, Kassubek J, Krismer F, Levin J, Lorenzl S, Morris H, Nestor P, Oertel WH, Rabinovici GD, Rowe JB, van Eimeren T, Wenning GK, Boxer A, Golbe LI, Litvan I, Stamelou M, Höglinger GU; Movement Disorder Society-Endorsed PSP Study Group.

Mov Disord. 2017 Jul;32(7):995-1005. doi: 10.1002/mds.27034. Epub 2017 May 13. Review.

PMID:
28500752
42.

Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria.

Höglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, Mollenhauer B, Müller U, Nilsson C, Whitwell JL, Arzberger T, Englund E, Gelpi E, Giese A, Irwin DJ, Meissner WG, Pantelyat A, Rajput A, van Swieten JC, Troakes C, Antonini A, Bhatia KP, Bordelon Y, Compta Y, Corvol JC, Colosimo C, Dickson DW, Dodel R, Ferguson L, Grossman M, Kassubek J, Krismer F, Levin J, Lorenzl S, Morris HR, Nestor P, Oertel WH, Poewe W, Rabinovici G, Rowe JB, Schellenberg GD, Seppi K, van Eimeren T, Wenning GK, Boxer AL, Golbe LI, Litvan I; Movement Disorder Society-endorsed PSP Study Group.

Mov Disord. 2017 Jun;32(6):853-864. doi: 10.1002/mds.26987. Epub 2017 May 3.

43.

Common Myths in the Use of Levodopa in Parkinson Disease: When Clinical Trials Misinform Clinical Practice.

Espay AJ, Lang AE.

JAMA Neurol. 2017 Jun 1;74(6):633-634. doi: 10.1001/jamaneurol.2017.0348. No abstract available.

PMID:
28459962
44.

Whole-genome sequencing suggests mechanisms for 22q11.2 deletion-associated Parkinson's disease.

Butcher NJ, Merico D, Zarrei M, Ogura L, Marshall CR, Chow EWC, Lang AE, Scherer SW, Bassett AS.

PLoS One. 2017 Apr 21;12(4):e0173944. doi: 10.1371/journal.pone.0173944. eCollection 2017.

45.

DeActs: genetically encoded tools for perturbing the actin cytoskeleton in single cells.

Harterink M, da Silva ME, Will L, Turan J, Ibrahim A, Lang AE, van Battum EY, Pasterkamp RJ, Kapitein LC, Kudryashov D, Barres BA, Hoogenraad CC, Zuchero JB.

Nat Methods. 2017 May;14(5):479-482. doi: 10.1038/nmeth.4257. Epub 2017 Apr 10.

46.

Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease.

Fox SH, Metman LV, Nutt JG, Brodsky M, Factor SA, Lang AE, Pope LE, Knowles N, Siffert J.

Mov Disord. 2017 Jun;32(6):893-903. doi: 10.1002/mds.26976. Epub 2017 Mar 30.

PMID:
28370447
47.

Neuroimaging and clinical features in adults with a 22q11.2 deletion at risk of Parkinson's disease.

Butcher NJ, Marras C, Pondal M, Rusjan P, Boot E, Christopher L, Repetto GM, Fritsch R, Chow EWC, Masellis M, Strafella AP, Lang AE, Bassett AS.

Brain. 2017 May 1;140(5):1371-1383. doi: 10.1093/brain/awx053.

PMID:
28369257
48.

Imaging biomarkers in Parkinson's disease and Parkinsonian syndromes: current and emerging concepts.

Saeed U, Compagnone J, Aviv RI, Strafella AP, Black SE, Lang AE, Masellis M.

Transl Neurodegener. 2017 Mar 28;6:8. doi: 10.1186/s40035-017-0076-6. eCollection 2017. Review.

49.

Parkinson disease.

Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag AE, Lang AE.

Nat Rev Dis Primers. 2017 Mar 23;3:17013. doi: 10.1038/nrdp.2017.13. Review.

PMID:
28332488
50.

Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials.

Espay AJ, Schwarzschild MA, Tanner CM, Fernandez HH, Simon DK, Leverenz JB, Merola A, Chen-Plotkin A, Brundin P, Kauffman MA, Erro R, Kieburtz K, Woo D, Macklin EA, Standaert DG, Lang AE.

Mov Disord. 2017 Mar;32(3):319-324. doi: 10.1002/mds.26913. Epub 2017 Feb 24. Review.

Supplemental Content

Support Center